|Bid||20.55 x 600|
|Ask||21.25 x 300|
|Day's Range||22.15 - 23.90|
|52 Week Range||3.65 - 23.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2018 - Mar 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.80|
RICHMOND, Calif. , Feb. 20, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its fourth quarter and full year 2017 financial results before the ...
According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.
RICHMOND, Calif., Feb. 13, 2018 /PRNewswire/ -- Sangamo Therapeutics (SGMO) yesterday presented preclinical data demonstrating the Company's engineering capabilities in T cell genome editing using zinc finger nucleases (ZFNs). Sangamo Scientist Sumiti Jain, Ph.D. delivered the presentation, "Dual Knock-Out of Endogenous T-Cell Receptor and Human Leukocyte Antigen and Site-Specific Insertion of a CD19-CAR: Implications for Allogeneic T Cell Therapy," at the Keystone Symposium on Emerging Cellular Therapies: T Cells and Beyond. Sangamo's T cell engineering capabilities have advanced rapidly in the last two years with recent improvements to the architecture of zinc finger nucleases (ZFNs).
RICHMOND, Calif., Feb. 12, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the appointment of Heather D. Turner as senior vice president and general counsel, effective immediately. ...
CLEVELAND and RICHMOND, Calif., Feb. 7, 2018 /PRNewswire/ -- Case Western Reserve University and Sangamo Therapeutics, Inc. (SGMO) today announced the award of an $11 million grant from the National Institutes of Health for a planned study of gene-edited T cells designed to eradicate persistent HIV infection in patients receiving anti-retroviral therapy, a combination of medicines that slows the rate at which HIV replicates. The grant will fund a clinical trial to test the hypothesis that treating patients with their own gene-edited T cells may lead to a sustained increase in T cell counts and eradication of latent HIV reservoirs. T cells (so-called because they develop in the thymus gland) are responsible for a variety of immune responses.
RICHMOND, Calif., Feb. 6, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the presentation of initial safety data from the CHAMPIONS Study, the Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis (MPS) type II, a rare disease also known as Hunter syndrome. The poster presentation titled "Update on phase 1/2 clinical trials for MPS I and MPS II using ZFN-mediated in vivo genome editing" includes safety data collected and prepared as of December 27, 2017 and describes the first six weeks of experience of the first patient in the CHAMPIONS study, who was treated November 13, 2017 with a dose of 5.00E+12 vg/kg of SB-913. The patient tolerated the infusion well. Mild (Grade 1) adverse events related to the study drug were reported on the fourth day after dosing as dizziness, weakness, and frequent urination, all of which resolved within one day without treatment. No other adverse events related to the study drug were observed.
Healthcare as an industry will only continue to grow and offers an exceptional place to invest. Drug stocks face a historically high chance of failure, but medical devices are an attractive addition for ...
RICHMOND, Calif., Jan. 8, 2018 /PRNewswire/ -- In meetings with investors this week and during a presentation Wednesday at the J.P. Morgan Healthcare Conference in San Francisco, Sangamo Therapeutics, Inc. (SGMO) Chief Executive Officer, Dr. Sandy Macrae will review the Company's growth and recent progress and outline key priorities and catalysts for the coming year. "Last year we made significant progress transitioning Sangamo from its previous research focus to a sustainable, fully integrated company that aims to translate cutting edge science into genomic medicines to transform patients' lives," said Dr. Macrae.
RICHMOND, Calif., Jan. 4, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Dr. Sandy Macrae , CEO of Sangamo, will present at the 36 th Annual J.P. Morgan Healthcare ...
On another record day for Wall Street, Dominion Energy moved to make an acquisition and Sangamo announced a new collaboration with Pfizer.
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.